Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Mediwound (MDWD)
NASDAQ:MDWD
Holding MDWD?
Track your performance easily
Earnings Data
Report Date
Mar 13, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.55Last Year’s EPS
-$0.19Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 26, 2024
|% Change Since: -4.85%
|Next Earnings Date:Mar 13, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant achievements including FDA approval for NexoBrid's pediatric use, strategic funding, and progress with EscharEx. However, financial challenges such as revenue decline, operating losses, and adjusted guidance were noted. While the company's strategic advancements are promising, financial metrics indicate areas for improvement.Company Guidance
During the third quarter of 2024, MediWound reported a revenue of $4.4 million, slightly down from $4.8 million in the same period in 2023. The gross profit stood at $0.7 million, representing 16% of total revenue, a decrease from the previous year's 90% due to a change in revenue mix. R&D expenses increased to $2.5 million, reflecting intensified activities for the pivotal EscharEx Phase III clinical trial, while SG&A expenses were reported at $3.2 million. The company's financial position remained robust with $46 million in cash and equivalents. MediWound anticipates a revenue of $20 million for 2024, down from prior guidance of $24 million due to reduced BARDA-related revenue. The quarter also saw a strategic $25 million investment led by Molnlycke Healthcare, bolstering MediWound's financial and strategic capabilities.FDA Approval for NexoBrid Pediatric Use
NexoBrid received FDA approval for pediatric use in the United States, expanding its indication to include patients from newborn to 18 years old with severe burns. This aligns its indications with those in the EU and Japan.
Commercial Progress of NexoBrid in the U.S.
NexoBrid saw a 43% quarter-over-quarter increase in revenue in the U.S., with over 70 burn centers submitting and securing approvals for its use.
WHO Designation for Enzymatic Debridement
The World Health Organization designated enzymatic debridement as essential for burn care, supporting NexoBrid's role in global emergency response and strategic stockpiling initiatives.
Significant Funding and Strategic Partnership
Secured $25 million through a private investment led by Molnlycke Healthcare, providing funding and access to commercial expertise.
EscharEx Phase III Study Preparations
Completed preparations for a Phase III study of EscharEx for venous leg ulcers and received EUR 16.25 million in funding for diabetic foot ulcers development.
---
MDWD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
MDWD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 26, 2024 | $17.33 | $16.90 | -2.48% |
| Aug 14, 2024 | $18.21 | $17.47 | -4.06% |
| May 29, 2024 | $17.79 | $16.01 | -10.01% |
| Mar 21, 2024 | $15.62 | $15.95 | +2.11% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Mediwound (MDWD) report earnings?
Mediwound (MDWD) is schdueled to report earning on Mar 13, 2025, TBA Not Confirmed.
What is Mediwound (MDWD) earnings time?
Mediwound (MDWD) earnings time is at Mar 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MDWD EPS forecast?
MDWD EPS forecast for the fiscal quarter 2024 (Q4) is -$0.55.
---